12 May 2015 - Deborah Wilkes
Archived
GlaxoSmithKline said sales of Flonase Allergy Relief had reached £65 million (US$101 million) in the first quarter of 2015, following the recent switch to OTC status in the US. The company noted that switching medicines from prescription to OTC status would be "an important component of growth" for its global Consumer Healthcare joint venture with Novartis.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.